^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EX103

    i
    Other names: EX103
    Company:
    ExcelMab
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    11ms
    Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=415, Recruiting, Guangzhou Excelmab Inc. | Phase classification: P1 --> P1/2 | N=138 --> 415
    Phase classification • Enrollment change
    |
    CD20 positive
    |
    EX103
    1year
    EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma (ASH 2023)
    Furthermore, EX103 demonstrates promising efficacy in heavily pretreated patients with R/R B-NHL, including some who have previously failed CAR-T treatment. The safety and efficacy of EX103 will be further evaluated in an ongoing clinical study.
    Clinical
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6)
    |
    IL6-L
    |
    EX103
    over1year
    EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma (ESMO 2023)
    The preliminary Disease Control Rate (DCR) is 84.6% (11/13). Conclusions The preliminary data show favorable safety and remarkable antitumor activity, even at low doses, in heavily pretreated patients with R/R B-NHL, including those who failed prior CAR-T therapy.
    Clinical
    |
    IL6 (Interleukin 6)
    |
    IL6-L
    |
    EX103